Astera Labs Has Slumped Since June: Why J.P. Morgan Still Sees 157% Upside
Astera Labs (ALAB) stock fell 19% to $181, down 29% in three months, despite strong Q3 revenue growth and upbeat guidance. J.P. Morgan maintains an Overweight rating and $465 price target, citing long-term growth potential. The stock trades at 32x forward earnings, below its one-year average of 72x.
How this was made
The 30-second read
Why it matters
The article provides no fresh corporate data; it mainly recaps prior earnings and analyst coverage, limiting actionable insight.
Market read
The piece is a recap of existing earnings and analyst opinion, offering minimal new trading impetus.
What to watch
Potential upside from the upcoming Orion rack‑scale AI solution is not yet reflected in the price.
Background
Astera Labs reported strong Q3 revenue growth and raised Q4 guidance, but the stock continues to slide as the broader AI chip sell‑off dominates market sentiment.
Ticker impact
Astera Labs shares fell 19% today amid a broader chip sell‑off; J.P. Morgan kept its Overweight rating with a $465 target, 157% above the current price.
likely further downside as investors price in sector weakness and skepticism about the target
No new corporate event; price move is reactionary to sector sell‑off and an unchanged, lofty target.
Market effects
Chip sector weakness is pressuring related stocks, including Astera Labs.
U.S. tech‑heavy indices are seeing modest declines.
Limited; the story is confined to U.S. semiconductor equities.
Counterpoint
If the Scorpio X platform gains traction faster than expected, the $465 target could become realistic, offering upside.
Key entities
- CompanyAstera Labs
U.S.-listed semiconductor firm (ticker ALAB).
- AnalystJ.P. Morgan
Maintains Overweight rating with a $465 price target.
